Overview

Study of Niacin in Glioblastoma

Status:
Recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

This is a single institution Phase I-II study to evaluate the tolerability and Maximum Tolerated Dose (MTD) (Phase I) and efficacy (Phase II) of adding Niacin CRT™ to standard first line treatment (concurrent Radiation Therapy (RT) and Temozolomide (TMZ) following by monthly TMZ - AKA Stupp protocol) in patients with newly diagnosed glioblastoma isocitrate dehydrogenase (IDH) wild type.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

AHS Cancer Control Alberta

Collaborator:

Tom Baker Cancer Centre

Treatments:

Niacin
Nicotinic Acids